SEC Form 4 · accession 0000899243-16-025947
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John G. Aunins
Officer — Chief Technology Officer & EVP
Period of report
Jul 27, 2016
Accepted (ET)
Jul 29, 2016 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 27, 2016 | S | 9,250 | $35.00 | D | 201,515 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person on March 28, 2016.